EAACI Guidelines
To add the references below to your reference management program: 1. Download the file; 2. Open your reference management program or EndNote; 3. Select File and import |
29 Articles |
-
EAACI Guidelines on Environmental Science for Allergy and Asthma—Recommendations on the Impact of Indoor Air Pollutants on the Risk of New-Onset Asthma and on Asthma-Related Outcomes
Agache, I., Annesi-Maesano, I., Cecchi, L., et al. Allergy. First published: 28 February 2025
-
EAACI guidelines on the management of IgE-mediated food allergy
Santos AF, Riggioni C, Agache I, et al. Allergy. First published: 30 October 2024
-
The impact of exposure to tobacco smoke and e-cigarettes on asthma-related outcomes: Systematic review informing the EAACI guidelines on environmental science for allergic diseases and asthma
Agache I, Ricci-Cabello I, Canelo-Aybar C, et al. Allergy. First published: 23 May 2024
-
EAACI guidelines on environmental science for allergy and asthma: The impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures
Agache I, Annesi-Maesano I, Cecchi L, et al. Allergy. First published: 02 April 2024
-
EAACI guidelines on the diagnosis of IgE-mediated food allergy
Santos AF, Riggioni C, Agache I, et al. Allergy. First published: 10 October 2023
-
EAACI guidelines on environmental science in allergic diseases and asthma – Leveraging artificial intelligence and machine learning to develop a causality model in exposomics
Shamji, MH, Ollert, M, Adcock, IM, et al. Allergy. First published: 05 February 2023
-
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Abdul Latiff, A., Abuzakouk, M., et al. Allergy. First published: 18 September 2021
-
EAACI biologicals guidelines – Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old
Agache, I., Akdis, C., Akdis, M., et al. Allergy. First published: 29 July 2021
-
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer, M, Magerl, M, Betschel, S, et al. Allergy. 2022; 77: 1961– 1990
-
World Health Organization global air quality guideline recommendations: Executive summary
Goshua, A, Akdis, C, Nadeau, KC. Allergy. 2022; 77: 1955– 1960
-
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
-
Dissemination of EAACI food allergy guidelines using a flexible, practical, whole school allergy awareness toolkit
Higgs, J., Styles, K., Bowyer, S., et al. Allergy. 2021; 76: 3479-3488
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., et al. Allergy. 2021; 76: 2337-2353
-
EAACI biologicals guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis
Agache, I., Akdis, C.A., Akdis, M., et al. Allergy. 2021; 76: 988-1009
-
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI biologicals guidelines
Agache, I, Rocha, C, Pereira, A, et al. Allergy. 2021; 76: 59– 70
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma
Agache, I, Song, Y, Posso, M, et al. Allergy. 2021; 76: 45– 58
-
EAACI biologicals guidelines—recommendations for severe asthma
Agache, I, Akdis, CA, Akdis, M, et al. Allergy. 2021; 76: 14– 44
-
EAACI guideline on the effective transition of adolescents and young adults with allergy and asthma
Roberts, G, Vazquez-Ortiz, M, Knibb, R, et al. Allergy. 2020; 75: 2734– 2752
-
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma
Agache, I, Song, Y, Rocha, C, et al. Allergy. 2020; 75: 1058– 1068
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Agache, I, Rocha, C, Beltran, J, et al. Allergy. 2020; 75: 1043– 1057
-
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
Agache, I, Beltran, J, Akdis, C, et al. Allergy. 2020; 75: 1023– 1042
-
EAACI guidelines on allergen immunotherapy: House dust mite-driven allergic asthma
Agache, I, Lau, S, Akdis, CA, et al. Allergy. 2019; 74: 855– 873
-
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update
Maurer, M, Magerl, M, Ansotegui, I, et al. et al. Allergy. 2018; 73: 1575– 1596.
-
EAACI Guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis
Roberts, G, Pfaar, O, Akdis, CA, et al. Allergy. 2018; 73: 765– 798
-
EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
Pajno, GB, Fernandez-Rivas, M, Arasi, S, et al. Allergy. 2018; 73: 799– 815
-
EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy
Sturm, GJ, Varga, E-M, Roberts, G, et al. Allergy. 2018; 73: 744– 764
-
EAACI guidelines on allergen immunotherapy: Executive statement
Muraro, A., Roberts, G., Halken, S., et al. Allergy. 2018; 73: 739-743
-
EAACI guidelines on allergen immunotherapy-Out with the old and in with the new
Agache, I. Allergy. 2018; 73: 737-738